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A wide variety of presentations in this session covered anumber of drugs that do not “neatly” fit in one or the
other sessions at this annual targeted therapy meeting. Dr.
Mark Green presented data on bendamustine, a novel alky-
lating agent and benzimidazole antimetabolite with signifi-
cant activity in lymphoproliferative disorders. In untreated,
extensive stage small cell lung cancer (SCLC), bendamustine
had 40% response rate (RR) as a single agent and 73% when
combined with carboplatin. Grades 3 to 4 leukopenia (46%)
was the most common toxicity. Ongoing SCLC trials evalu-
ate bendamustine with frontline irinotecan and as a single
agent in the second line.
Dr. David Ettinger presented data on amrubicin, a
synthetic anthracycline that has been extensively evaluated in
SCLC. RR more than 20% was seen in a phase II study of
patients with platinum refractory SCLC. Clinical evaluation
of this agent is ongoing including a phase III trial of cisplatin
and amrubicin versus cisplatin and etoposide.
Pralatrexate, FDA approved for treatment of peripheral
T-cell lymphoma, is a novel antifolate. Pralatrexate is trans-
ported into cells by reduced folate carrier (RFC) and inhibits
dihydrofolate reductase. Activity seems independent of thy-
midylate synthase expression, a potential mechanism of pem-
etrexed resistance. Dr. Mark Kris outlined multiple trials at
Memorial Sloan Kettering evaluating pralatrexate, including
a phase I trial in 35 patients with non-small cell lung cancer
(NSCLC) with two complete responses and RR of 8%. He
outlined a randomized phase II trial of pralatrexate versus
erlotinib after platinum-based therapy in current or former
smokers.
Dr. Grace Dy presented a detailed evaluation of RFC-1,
the primary mechanism of pralatrexate transport into cells.
RFC expression is reduced with folate deprivation, and poly-
morphisms in RFC-1 may be related to response to antifolate
therapies. Decreased drug transport into cells by RFC-1 is a
mechanism of methotrexate resistance, which may be over-
come by pralatrexate given higher affinity for the transporter.
Dr. Everett Vokes presented data on picoplatin, a novel
platinum compound designed to overcome platinum resis-
tance. It has a favorable toxicity profile with respect to
neurotoxicity and neuropathy, but myelotoxicity is seen. In a
phase II study of platinum refractory SCLC (progression
0–180 days after platinum-based therapy), survival compared
favorably with historical controls (26 weeks). In the Study of
Picoplatin Efficacy After Relapse (SPEAR) trial, picoplatin is
compared with best supportive care in the second line after
progression on platinum agent, and data should be presented
at the American Society of Clinical Oncology (ASCO) 2010.
Dr. Glen Weiss presented data on TH-302, a novel
delivery system of a novel hypoxia activated cytotoxic agent.
The compound is an alkylator, bromo-isophosphoramide
mustard that is activated in hypoxic environments. TH-302
has been evaluated as monotherapy and with cytotoxics. In
relapsed/refractory SCLC, four of seven patients had stable
disease (SD) or partial response (PR) with some skin toxicity
and oral mucositis as dose-limiting toxicities (DLTs). There
is an ongoing expansion at the maximum tolerated dose in
SCLC. Phase I studies for TH-302 in combination with
gemcitabine, taxotere, or pemetrexed are being conducted.
Dr. Ana Oton presented data about CS-7017, a small
molecule peroxisome proliferator-activated receptor
(PPAR)- agonist. PPAR- agonists are hypothesized to act
by activating retinoid X receptor ligand transcription with
resultant apoptosis, cell cycle arrest, and antiangiogenic
changes. In vivo, CS-7017 demonstrates synergy with carbo-
platin and taxol. In a phase I study of 31 patients, maximum
tolerated dose was not reached, with 1 PR and 12 SD.
Adiponectin levels were followed as a biomarker of PPAR-
activation, and levels increased significantly with therapy. Dr.
Oton outlined several planned randomized phase II NSCLC
clinical trials in the frontline (carboplatin/paclitaxel) and
second-line setting (erlotinib).
Activin, a member of the transforming growth factor-B
family, signals though Smad-dependent pathways and re-
duces bone mass through osteoblast inhibition and osteoclast
stimulation. Activin A, also known as erythrocyte differenti-
ating factor, is involved in red blood cell maturation and
development. Activin overexpression has been associated
with numerous malignancies.1 Preclinically, activin stimu-
lates cell line growth, which can be blocked with siRNA
directed toward activin targets (Follistatin and INHBA). Dr.
David Beer presented data related to ACE-011, a fully hu-
manized activin antagonist. A murine version of the antibody
inhibited tumor development and improved bone strength and
survival in a myeloma model. Preclinical data also demon-
strate improved red blood cell indices with ACE-011. Clini-
cal studies in myeloma have been conducted, and a phase II
trial for platinum-related anemia in NSCLC is planned.
Dr. Chandra Belani presented data on Volociximab, a
monoclonal antibody targeting the 51 integrin, with mul-
tiple effects on endothelial cell development and formation of
neovasculature. In a phase Ib study, escalating doses were
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combined with standard dose carboplatin and taxol as front-
line NSCLC therapy. Three serious adverse events were
attributed to the drug (arterial thrombosis, DVT), but no DLT
was reached, and there were eight patients with PR (28%) and
17 with SD (57%). Further studies are planned.
Dr. Mark A Socinski presented data on three fully human-
ized monoclonal antibodies in NSCLC. Necitumumab has ac-
tivity similar to cetuximab and is being evaluated in a phase III
NSCLC trial combined with frontline pemetrexed-cisplatin
(nonsquamous) or gemcitabine-cisplatin (squamous). Cixutu-
mumab targets insulin-like growth factor receptor and is being
evaluated in multiple phase II trials in NSCLC (frontline che-
motherapy  bevacizumab, frontline chemotherapy plus cetux-
imab, and second-line erlotinib) and extensive stage SCLC
(cisplatin  etoposide). IMC-3G3 targets platelet derived
growth factor receptor- with greater potency than imatinib and
is being evaluated in phase II studies with cytotoxics.
Dr. Jonathan Kurie presented data on novel approaches
to preventing metastatic disease. In preclinical models, the
miR-200 family plays a central role in metastatic potential.
Potential upstream regulators include Jagged2, and down-
stream targets include vascular endothelial growth factor
receptor 1 and BMP4. These targets help modulate miR-200
function in coordinating interaction between tumor and stro-
mal cells and are potential therapeutic targets.
Malignant cells must stabilize telomere length to con-
tinue replication. Up to 90% of human malignancies have
detectable telomerase activity, with increased activity corre-
lating with worse outcomes. Dr. Jerry Shay presented data on
Imetelstat, a telomerase inhibitor that controls lung metastasis
and leads to durable response when combined with chemo-
therapy in preclinical models. Imetelstat is currently being
evaluated in the phase I/II setting in multiple malignancies
including NSCLC, and it has demonstrated safety as a single
agent or combined with cytotoxic therapy.
Dr. Roy Herbst presented data on PX-478, a novel
HIF-1 inhibitor, currently the only small molecule inhibitor
in this class in clinical evaluation. PX-478 inhibits HIF-1
expression in preclinical models and has substantial antitu-
mor activity in NSCLC and SCLC xenograft models. An
ongoing phase I study is nearing completion, and there were
no DLTs in 40 evaluated patients.
Dr. Edward Garon presented data supporting a role of
estrogen in NSCLC. In vitro and in vivo data demonstrate
growth promotion effects of estrogens that are inhibited by
fulvestrant. The Women’s Health Initiative noted increased
NSCLC mortality in women receiving exogenous estrogen
therapy,2 and observational data demonstrates that women on
antiestrogen therapy for breast cancer have less risk of death
from lung cancer.3 Dr. Garon discussed an ongoing, random-
ized phase II trial comparing erlotinib alone or combined with
fulvestrant for which extensive correlative evaluation is
planned (Figure 1).
The ER pathway interacts with other growth signaling
pathways (epidermal growth factor receptor, RAS-mitogen-
activated protein kinase, and phosphatidylinositol 3-kinase).4
Dr. Jill Siegfried presented data relating aromatase to lung
cancer. In xenograft models, anastrozole inhibits tumor
growth in ovariectomized mice, decreasing tumor number
and size. Dr. Siegfried discussed a planned phase II clinical
trial for postmenopausal women with advanced NSCLC who
will be randomized to best supportive care or fulvestrant 
anastrazole in maintenance after frontline chemotherapy.
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FIGURE 1. A schema of an ongo-
ing trial of erlotinib with or with-
out fulvestrant. Patients receive er-
lotinib 150 mg orally once a day
with or without fulvestrant (500
mg days 1, 15, 29, and every 28
days thereafter). Patients are ran-
domized in a 1:2 fashion and strat-
ified for gender and performance
status. Blood and tissue are being
collected for correlative work.
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